Navigation Links
Jeffrey Wasserstein Joins Greenhill as Managing Director Focused on the Pharmaceutical Sector
Date:9/10/2012

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Greenhill & Co., Inc. (NYSE: GHL), a leading independent investment bank, announced today that Jeffrey Wasserstein has joined the Firm in New York to enhance its focus on the pharmaceutical sector.

Mr. Wasserstein has a 20 year history in the pharmaceutical industry in corporate development and commercial operating roles for a series of pharmaceutical companies.  Most recently he served as Senior Vice President of Business Development & Strategy at Fougera Pharmaceuticals, which was recently sold to the Sandoz division of Novartis AG.  Prior to his time at Fougera he spent five years at Dr. Reddy's Laboratories, a leading global generic pharmaceutical company, as founder and President of a branded specialty pharmaceutical subsidiary focused on dermatology as well as the Executive Vice President of North America and a member of Dr. Reddy's Global Management Council.  He began his career in the sector at Schering-Plough Corporation, where he started in a legal role and rose to first head of Corporate Business Development, then President of Schering Canada and later Senior Vice President of the parent company.  Prior to his time at Schering-Plough, he was an attorney at Wachtell, Lipton, Rosen & Katz for six years, focused on mergers and acquisitions advice.

Scott L. Bok, Chief Executive Officer of Greenhill, said, "The health care sector has become a very important part of our business, as an increasing number of companies in health care services, health care devices and pharmaceuticals have opted for our unconflicted, client-focused approach to advising clients on important transactions.  With the addition of Jeff we are significantly increasing our knowledge of the trends and opportunities in the pharmaceutical sector, as well as our access to a much larger range of companies in that sector."

Jeffrey Wasserstein said, "I am very pleased to be joining Greenhill, where I have known some of its partners for many years.  In my new role I can build upon my many relationships in the industry as well as my significant experience as a corporate development and operating executive and as an external advisor.  I look forward to utilizing my deep industry knowledge, an insider's appreciation for the many challenges facing the senior management and boards of companies in the pharmaceutical sector and my significant transaction experience to advise pharmaceutical companies on important transactions and other matters."

Greenhill & Co., Inc. is a leading independent investment bank focused on providing financial advice on significant mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments.  It acts for clients located throughout the world from its offices in New York, London, Frankfurt, Stockholm, Sydney, Tokyo, Toronto, Chicago, Dallas, Houston, Los Angeles, Melbourne and San Francisco.

Contact:
Christopher T. Grubb
Chief Financial Officer
Greenhill & Co., Inc.
(212) 389-1800


'/>"/>
SOURCE Greenhill & Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AgaMatrix elects Jeffrey B. Kindler to its Board of Directors
2. Financier Jeffrey Epstein And Mount Sinai Hospital Support 3D Mammograms For Breast Cancer
3. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
4. The Largest Private Funder Of Melanoma Research Receives Vital Support From Activist Jeffrey Epstein
5. Gerald E. Quirk Joins Choate, Hall & Stewart LLP as Co-Chair of Life Sciences Group
6. Dr. Magnus Persson Joins Cerecors Board of Directors
7. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
8. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
9. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
10. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
11. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/6/2017)... CINCINNATI , July 6, 2017 ThriveRx, the nutrition division ... and their families to thrive on nutrition support. To celebrate ... The new site has a fresh new look with improved organization to ... ... ...
Breaking Medicine Technology:
(Date:7/22/2017)... ... July 22, 2017 , ... More than ... of patients not requiring pain medication after three months post-operatively. However, researchers presenting ... Meeting today in Toronto, Ontario, Canada found that those patients who were filling ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie provider ... in a community wide charity event with the goal of bringing in support for ... woman who lives with epilepsy, recently launched a charity campaign of her own by ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... Philadelphia and Theater of Witness , was awarded a $300,000 grant ... humanities program which fosters empathy, comfort with ambiguity and the recognition of one’s ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated ... life a decade after surgery, though activity levels decline over time. The study, ...
Breaking Medicine News(10 mins):